Stuart BoyceManaging Director (MD) of S&B & Chief Information Officer (CIO) SIA in HealthcareMy early career focused on customer service and product sales in property and retail banking, both of which I enjoyed. However, due to a family background in business intelligence in healthcare, I decided to join S&B which specialises in BI with the intention of combining my customer service and product sales experience with business intelligence and informatics. I initially worked on various business intelligence projects with pharmaceutical companies and NHS organisations using several BI tools including Board MIT, Cognos, Qlik etc. however, as of 2018 we standardised on Microsoft Power BI. In 2020 I assumed responsibility for S&B as Managing Director and in 2022 Chief Information Officer for the Strategic Intelligence Alliance in Healthcare (SIA) a partner organisation. Most recently we have been working on projects with Imperial College London’s Neonatal Unit on the National Neonatal Research Database, Suffolk and North East Essex ICS on Quality of Life, The British Society for Heart Failure on their 25*25 initiative, Cancer Services Performance with the East of England amongst others. In addition, my R&D team and that of the SIA, have been working on Medicines optimisation, Early Diagnosis in Diabetes, Early Diagnosis in Cancer, Cancer Waiting Times Performance, Learning Difficulties, Mental Health, Eating Disorders and Anxiety and Depression Disorders. As a specialist in Business Intelligence (BI) and data engineering in healthcare, I have over 15 years’ experience using both open and secure datasets to provide bespoke BI models and visualisations to inform decision making and transformation. I primarily use SQL Server, Power BI and QGIS platforms to deliver these insights. As part of the Strategic Intelligence Alliance, we are creating and delivering cutting-edge tools to deliver actionable and accessible intelligence to NHS Hospital Trusts, CCG's and ICB/STP's as well as regional networks in specific disease areas. These range from Medicines Optimisation tools, which are essentially "off the shelf" to bespoke Open Data models built from over 30 datasets to create a comprehensive analysis of the environment and pathways relating to a specific disease area.